Multidrug-resistant Gram-negative bacteria: Difference between revisions
From IDWiki
No edit summary |
(→) |
||
| Line 2: | Line 2: | ||
*[[Ceftolozane-tazobactam]] (Zerbaxa) |
*[[Ceftolozane-tazobactam]] (Zerbaxa) |
||
| + | **May be better for multidrug-resistance [[Pseudomonas]] (or at least more experience with it) |
||
| − | |||
| − | * |
||
| − | |||
*[[Ceftazidime-avibactam]]: available through Special Access Program |
*[[Ceftazidime-avibactam]]: available through Special Access Program |
||
| + | **Adds coverage of some carbapenemases and AmpC |
||
*[[Fosfomycin]] |
*[[Fosfomycin]] |
||
** |
** |
||
Revision as of 09:31, 26 August 2020
Management
- Ceftolozane-tazobactam (Zerbaxa)
- May be better for multidrug-resistance Pseudomonas (or at least more experience with it)
- Ceftazidime-avibactam: available through Special Access Program
- Adds coverage of some carbapenemases and AmpC
- Fosfomycin
- Colistin
- Cefiderocol: available through Special Access Program as well as preapproval by manufacturer
- Meropenem-vaborbactam: still awaiting Health Canada Drug Review
- Imipenem-relebactam (really imipenem-cilastatin-relebactam): still awaiting Health Canada Drug Review
